1. Volume 64, Issue 3, Pages 1071-1079 (September 2003)
Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States 
Austin G. Stack, Donald A. Molony, Noor S. Rahman, Akinsansoye Dosekun, Bhamidipati Murthy 
Kidney International 
Volume 64, Issue 3, Pages (September 2003)
DOI: /j x
Copyright © 2003 International Society of Nephrology Terms and Conditions

2. Figure 1
Adjusted Cox survival curves for new diabetic end-stage renal disease (ESRD) patients with and without congestive heart failure (CHF) treated with peritoneal dialysis (PD) versus hemodialysis (HD). Adjusted for age at study start, gender, race, cause of ESRD, hypertension, coronary artery disease (CAD), peripheral vascular and cerebrovascular disease, tobacco use, chronic lung disease, acquired immunodeficiency syndrome (AIDS), neoplasm, serum albumin, body mass index (BMI), hematocrit, estimated glomerular filtration rate (GFR), and pre-ESRD erythropoietin use. For CHF, PD/HD comparison, P < ; no CHF PD/HD comparison, P < 0.01.
Kidney International  , DOI: ( /j x)
Copyright © 2003 International Society of Nephrology Terms and Conditions

3. Figure 2
Adjusted Cox survival curves for new nondiabetic end-stage renal disease (ESRD) patients with and without congestive heart failure (CHF) treated with peritoneal dialysis (PD) versus hemodialysis (HD). Adjusted for age at study start, gender, race, cause of ESRD, hypertension, coronary artery disease (CAD), peripheral vascular and cerebrovascular disease, tobacco use, chronic lung disease, acquired immunodeficiency syndrome (AIDS), neoplasm, serum albumin, body mass index (BMI), hematocrit, estimated glomerular filtration rate (GFR), and pre-ESRD erythropoietin use. For CHF, PD/HD comparison, P < ; no CHF PD/HD comparison, P = NS.
Kidney International  , DOI: ( /j x)
Copyright © 2003 International Society of Nephrology Terms and Conditions